BOJ Holds Rates at 1% as Inflation Outlook Eases, October Rate Hike Still Possible 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
US Stock Futures Rise as AI Optimism Lifts Nvidia, Microsoft, Amazon While Apple Slips 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Oil Prices Ease After Sharp Rally as Trump Warns of More Action Against Iran 
Asian Currencies Hold Steady After Fed Decision as Dollar Finds Support 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Iran Warns of Retaliation as Trump Threatens New Strikes, Oil Risks Intensify 
BOJ Rate Decision in Focus as Sticky Inflation, Weak Yen Shape USD/JPY and Nikkei Outlook 
Asian Stocks Slip as Fed Holds Rates, Samsung Earnings Fail to Lift AI Sentiment 
US Jobs Report, Fed Outlook, and Big Tech Earnings Put Stock Market in Focus 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Citi Says Sharp TOPIX Drop Could Push USD/JPY Lower as Yen Gains Momentum 
Eli Lilly gets a subpoena from the U.S. Department of Justice with regards to its manufacturing factory in New Jersey that produces COVID-19 treatment called bamlanivimab. Based on the report, the DOJ wants the pharmaceutical company to forward some documents.
As per Reuters, while it was not specified what documents are being requested by the officials, they are something related to Eli Lilly’s factory site in Branchburg, New Jersey. The company said that it is actively participating and fully cooperating with the investigation.
The issue with Eli Lilly’s NJ plant
Earlier this month, some of Eli Lilly’s employees alleged that an executive in the NJ plant altered the documents so it can pass quality control without a problem. The papers are required by regulators for the operation of the company’s factory, but with the modification, the employees feared it would cause serious quality control issues.
It was relayed that in November 2019, inspectors from the U.S. Food and Drug Administration were sent over to check Eli Lilly’s Branchburg factory. They discovered that much of the data related to manufacturing processes were deleted while others were not inappropriately audited.
The pharmaceutical company is also said to be facing issues with its quality control and production at its plant in Indianapolis. This is the site where bamlanivimab and other medicines are being bottled.
Lilly conducting its own internal probe
As per Financial Post, Eli Lilly also launched its own investigation concerning the allegations. The company also hired counsel who will carry out an independent probe in its New Jersey facility.
“Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority,” the firm stated.
In any case, while the investigation is ongoing, Eli Lilly published the subpoena issued to them by the DOJ. This move shows that the company is being transparent with the investigation and doing its best to resolve the problems too. Meanwhile, the company could not comment further on the case as of this time since a conclusion has not been reached yet.
